Cartiva Injury Lawyers Appointed to Leadership Roles in Federal MDL

A U.S. District Judge overseeing the federally consolidated Cartiva implant litigation has appointed a group of plaintiff attorneys to leadership roles responsible for coordinating the MDL and representing plaintiffs' interests. The Cartiva synthetic cartilage implant was marketed as an alternative to big toe fusion surgery for patients with degenerative arthritis at the base of the big toe. The manufacturer promoted an 87% success rate during pre-market testing, but post-market FDA data showed actual success rates of only 21% to 46%, prompting the FDA to issue a recall in October 2024. Plaintiffs allege the implants were defectively designed and prone to loosening, fracture, bone erosion, chronic pain, and complete failure requiring additional surgery. The leadership appointments represent an early procedural step as the court establishes procedures for coordinated discovery, future bellwether trials, and potential settlement discussions among the nationwide Cartiva implant claims.

This is a curated brief from the PlaintiffWire news desk. Read the original report at AboutLawsuits.